Publications by authors named "Daniel A Scott"

Claim this Profile
S
Safety and immunogenicity of a booster dose of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 2, open-label extension of a phase 1/2 randomised controlled trial.
Babalwa Jongihlati, Nathan Segall, Stanley L Block, Judith Absalon, John Perez, Daniel A Scott

Lancet Infect Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamics of Respiratory Syncytial Virus Illness and Serology During Pregnancy and Infancy in the United States and South Africa.
Shabir A Madhi, Eric A F Simões, Nicola P Klein, Agnieszka Zareba, Philip R Dormitzer, Daniel A Scott

Open Forum Infect Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of a 4-Dose 20-Valent Pneumococcal Conjugate Vaccine Series in Infants: A Randomized Trial.
Gabriella Hajdu, Teena Hughes, G Laïssa Ouedraogo, Laurence Flint, Mariano Young, Daniel A Scott

Pediatrics· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3, Single-arm Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through <18 Years of Age.
Jay Meyer, Peter Silas, G Laïssa Ouedraogo, Kathleen McElwee, Georgina Keep, Daniel A Scott

Pediatr Infect Dis J· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.
Shelly Senders, Nicola P Klein, Noor Tamimi, Allison Thompson, Gary Baugher, Daniel A Scott

Pediatr Infect Dis J· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optic atrophy in prematurity: pathophysiology and clinical features.
Daniel Ar Scott, Michael Tm Wang, Helen V Danesh-Meyer, Sarah Hull

Clin Exp Optom· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan.
Miwa Haranaka, Joon Young Song, Kuo-Chin Huang, Richard de Solom, Masako Yamaji, Daniel A Scott

Vaccine· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age.
Kai Chu, Yuemei Hu, Hongxing Pan, Jingliang Wu, Dandan Zhu, Daniel A Scott

Hum Vaccin Immunother· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial.
Michael W Simon, Regine Bataille, Nicole S Caldwell, Bradford D Gessner, Luis Jodar, Daniel A Scott

Hum Vaccin Immunother· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential for Maternally Administered Vaccine for Infant Group B Streptococcus.
Shabir A Madhi, Annaliesa S Anderson, Judith Absalon, David Radley, Raphael Simon, Daniel A Scott

N Engl J Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old.
David Fitz-Patrick, Mariano Young, Kari Yacisin, Kathleen McElwee, Todd Belanger, Daniel A Scott

Vaccine· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial.
Kevin Cannon, Jose F Cardona, Kari Yacisin, Allison Thompson, Todd J Belanger, Daniel A Scott

Vaccine· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease.
Charu Sabharwal, Vani Sundaraiyer, Yahong Peng, Lisa Moyer, Todd J Belanger, Daniel A Scott

Hum Vaccin Immunother· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.
Brandon Essink, Charu Sabharwal, Kevin Cannon, Robert Frenck, Himal Lal, Daniel A Scott

Clin Infect Dis· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine.
James T Peterson, Agnieszka M Zareba, David Fitz-Patrick, Brandon J Essink, Daniel A Scott

J Infect Dis· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine.
Ann R Falsey, Edward E Walsh, Daniel A Scott, Alejandra Gurtman, Agnieszka Zareba

J Infect Dis· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.
Beate Schmoele-Thoma, Agnieszka M Zareba, Qin Jiang, Mohan S Maddur, Rana Danaf, Daniel A Scott

N Engl J Med· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine.
Edward E Walsh, Ann R Falsey, Daniel A Scott, Alejandra Gurtman, Agnieszka M Zareba

J Infect Dis· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy.
Eric A F Simões, Kimberly J Center, Alan T N Tita, Kena A Swanson, David Radley, Daniel A Scott

N Engl J Med· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination.
Kevin Cannon, Charles Elder, Mariano Young, Daniel A Scott, Ingrid L Scully

Vaccine· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a multidose vial formulation of 13-valent pneumococcal conjugate vaccine administered with routine pediatric vaccines in healthy infants in India: A phase 4, randomized, open-label study.
Sanjay Kewalchand Lalwani, Padmasani Venkat Ramanan, Amita Sapru, Balasubramanian Sundaram, Bela Hasmukh Shah, Daniel A Scott

Vaccine· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States.
Shelly Senders, Nicola P Klein, Erik Lamberth, Allison Thompson, Jelena Drozd, Daniel A Scott

Pediatr Infect Dis J· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3, multicenter, single-arm, open-label study to assess the safety, tolerability, and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine in Japanese participants aged 6-64 years who are considered to be at increased risk of pneumococcal disease and who are naive to pneumococcal vaccines.
Yoshitaka Yamazaki, Masanori Ikeda, Takayuki Imada, Kenji Furuno, Tomoyuki Mizukami, Daniel A Scott

Vaccine· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age.
Nicola P Klein, Paula Peyrani, Kari Yacisin, Nicole Caldwell, Xia Xu, Daniel A Scott

Vaccine· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 4 study of the safety of the 13-valent pneumococcal conjugate vaccine in children 6 to 17 years of age in India.
Jugesh Chhatwal, Amita Sapru, Balasubramanian Sundaram, Bhaskar Shenoy, Rohit Chand, Daniel A Scott

Vaccine· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis